why choose us

First received: October 13, 2022

Clinical Trial: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: HER2-negative Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)

Brief Summary: This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments.Participants in this study in addition to the standard care chemotherapy will also receive the drug alpelisib and L-NMMA.The therapies will be administered every 3 weeks (1 cycle) until disease progression, toxicity or until…

Read more